In the observed group of 104 NSCLC patients with ALK or ROS1 gene rearrangements treated with ALK or ROS1 inhibitors, we observed a median PFS of 19 months and a median OS of 58 months. The gene discussed is ALK; the disease is non-small cell lung carcinoma.